Introduction

32
In Australia, the Pharmaceutical Benefits Advisory Committee (PBAC) is responsible for advising the 33 government as to which medicines should be subsidised on the Pharmaceutical Benefits Scheme 34 (PBS). In fulfilling this role, the PBAC is the steward of a large sum of public money: for the 12 35 months ending 30 June 2015, for example, total PBS spending amounted to $9.07 billion 1 . 36 The PBAC makes its recommendations primarily on the basis of evidence of clinical effectiveness, 37 safety and cost effectiveness derived from clinical trials and population-based observational studies. 38
The PBAC also takes into account other factors, such as equity, in its consideration of what does, or 39 does not, constitute "value for money". In this context, the term "equity" refers to access to PBS 40 listed drugs in a manner that takes into account the distribution of benefits and potential harms 41 based on factors such as prognosis, disease severity, age, distributional effect, context (eg. 42 emergency or prevention), socioeconomic and geographical status and other issues not typically 43 considered as part of quality of life measurements 2 . 44
Previous analyses of PBAC recommendations demonstrated that the PBAC has been broadly 45 consistent in its use of economic efficiency as a key criterion for decision making 3, 4 . The probability 46 of a positive recommendation does increase with lower incremental cost effectiveness ratios but 3 there is no evidence of a fixed threshold for the value of a life year or a quality adjusted life year 48 (QALY) 4 . Importantly, the PBAC has been found to actualise equity considerations by accepting a 49 higher incremental cost effectiveness ratio (ICER) for medicines addressing a high unmet clinical 50 need 5-7 and/or greater uncertainty in the available clinical evidence for rare diseases 8 . 51
Further, the PBAC in its deliberation may consider the 'Rule of Rescue' (RoR). The consideration and 52 application of RoR allows the PBAC to potentially reverse a decision not to recommend listing on the 53 because of its consideration of comparative cost-effectiveness (and any other relevant factors). 54
However, evidence (based on the published Public Summary Documents (PSDs) for past PBAC 55 recommendations) indicates that the RoR has been applied infrequently by the PBAC and that there 56 were few documented examples where application of the RoR has led to a positive PBAC 57 recommendation 9 . PBAC consideration of the RoR requires the following four factors to be met: (1) 58 no alternatives exist in Australia (2) the medical condition is severe, progressive and expected to 59 lead to premature death (3) the medical condition applies to only a very small number of patients 60 and (4) the proposed medicine provides a worthwhile clinical improvement sufficient to qualify as a 61 rescue from the medical condition 2 . However, the relative influence/weight of the RoR factors is not 62 quantitatively pre-defined. Importantly, the RoR as with other relevant factors supplements, rather 63 than substitutes for evidence based consideration of cost-effectiveness 2 . 64
The PBAC also provides advice on the inclusion of medicines on the Life Savings Drugs program 65 (LSDP) 9 . The LSDP sits outside the PBS to provide an alternate funding arrangement for access to 66 medicines that are not eligible for funding under the PBS due to unacceptable cost effectiveness. 67
While those making submissions to the PBAC occasionally include population survey data on 68 community preferences, assessments of equity are most commonly based on assumptions about 69 community priorities. Given the central role that the general public has in funding publicly 70 subsidised health technologies through taxes, and as beneficiaries of these technologies, it is 71 increasingly recognised that this is inadequate, and that more information is needed about public 72 preferences when making decisions about the funding of new medicines 10-12 . 73 Around the world, government agencies responsible for the selection and reimbursement of 74 prescribed medicines and other health technologies are increasingly concerned with how best to 75 incorporate community preferences into their decision making 13, 14 . In Australia, the PBAC currently 76 considers patients and the public views through consumer representation on the Committee, via an 77 online consumer input process, as well as through consumer hearings convened by the PBAC for 78 selected submissions. Recent examples of such hearings include those for lymphoma (brentuximab 79 vedotin, bendamustine, idelalisib and obinutuzumab), which were considered at the March 2015 80 PBAC meeting 15 , and for ovarian cancer and Morquio A syndrome (olarparib and elosulfase alfa 81 respectively) which were considered at the March 2016 PBAC meeting 16 . 82 Another important approach to eliciting consumer preferences, which supplements more direct 83 forms of consumer engagement, is to conduct surveys of representative samples of the community. 84
These have been used previously to support policy concerning the funding of cancer drugs in the 85 UK 17 , to assess the preferences for the funding of orphan drugs 18 and to understand public 86 agreement with policies aimed to facilitate access to life-extending drugs used at the end of 87 patients' lives 19 . To date, however, no representative community survey has explored how members 88 of the Australian community rank various criteria according to their importance to funding decisions 89 for prescribed medicines. We therefore conducted an on-line survey of 3080 Australians aged 18 90 years or older in order to measure community preferences for the distribution of the benefits and 91 costs of PBS listed drugs. 92
Methods
93
We undertook a cross sectional web based survey of 3080 adult Australians aged 18 years or older. 94 This paper focuses on the findings from the ranking exercise conducted as part of the present study. 95 SSI, a market research company with a large online panel (~ 409,000 registered members) was used 96 to recruit survey participants. Recruitment was controlled by gender, age and geographical area 97 (state of residence) in order to ensure that the sample was representative of the general adult 98 Australian population. Participants were compensated for their time and received 'reward points' 99 averaging $1.40 from the panel provider. Selection of the 12 prioritisation criteria was informed by 100 both the published literature and criteria currently used by the PBAC when assessing new medicines 101 for public subsidy. 5, 6, 7, 8, 9, 10 The 12 prioritisation criteria, were: (1) severity of disease (2) availability 102 of alternative medicine (3) significant innovation (4) carer burden (5) disadvantaged populations (6) 103 children (7) end-of-life treatments (8) cancer treatments (9) rare disease therapies (10) cost to the 104 PBS and savings to patient (11) medicines that help patients return to work (12) Life-style related 105 diseases and individual responsibility. 106
The survey asked respondents which criteria they believed were the most important in healthcare 107 spending and resource allocation. Respondents were asked to rank the 12 prioritisation criteria from 108 one to 12, with one being the most important criterion. The survey was pilot tested with 111 109 participants in August 2015. An additional question regarding the state of residence was added after 110 pilot testing. The full survey was administered during October 2015 and closed when our target of 111 3000 complete responses was achieved. Socio-demographic data were collected to test associations 112 between respondents' views on the prioritisation criteria and demographic characteristics. 113
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Statistical analysis
The four prioritisation criteria that were assigned the highest priority, also received the largest 134 number of top 3 rankings: disease severity (n= 1966, 21.3%), medicines for children (n= 1260, 135 13.6%), cancer medicines (n= 1112, 12.0%), and medicines targeting a disease for which no other 136 medicine is available (n= 957, 10.4%). 137
Medicines targeting a disease for which there is no alternative treatment available were ranked least 138 important (i.e. with a respondent's assigned rank order of 12) by 7.7% of respondents compared to 139 2.4%, 1.9% and 1.0% for medicines treating severe/life threatening diseases, treating a disease 140 affecting children and medicines for cancer patients, respectively. 141 'End-of-life treatments' and 'rare disease therapies' received the least number of highest priority 142 rankings (2.0% and 1.7% respectively). 143
Relationship between respondent characteristics and prioritisation 144 preferences 145 Country of birth (p= 0.04), employment status (p= 0.04) and having dependent children (p= 0.0001) 146
were associated with funding preferences (see Supplementary file). Respondents who were born 147 overseas were significantly more likely to assign a top priority to medicines that help patients return 148 to work (OR= 1.57, 95% CI= 1.06 to 2.32, p= 0.02), and to medicines targeting life style unrelated 149 diseases (OR= 1.57, 95% CI= 1.01 to 2.42, p= 0.04) than to prioritise disease severity, compared to 150 those born in Australia. Respondents with dependent children were significantly more likely to 151 assign a top ranking to medicines targeting diseases affecting children (OR= 2.04, 95% CI= 1.52 to 152 2.78, p<0.0001), and to cancer medicines (OR= 1.45, 95% CI= 1.01 to 2.04, p= 0.04). Respondents 153 who are in part time employment were significantly less likely to assign a top finding priority to 154 medicines targeting rare diseases than those working full time (OR= 0.19, 95% CI= 0.05 to 0.66, p= 155 0.01). Compared to respondents who were in full time employment, respondents who were neither 156 in employment nor unemployed (i.e. 'other' category, for example those who were looking after a 157 home or studying full time) were significantly more likely to assign a top ranking to medicines 158 targeting diseases that affect patients who are not financially well off (OR= 1.72, 95% CI= 1.02 to 159 2.87, p= 0.04). Further, these respondents were significantly less likely to allocate the highest 160 funding priority to medicines targeting life style unrelated diseases (OR= 0.15, 95% CI= 0.03 to 0.63, 161 p= 0.01) compared with those in full time employment. 162
There was also some evidence that health status (P= 0.06) and private health insurance (P= 0.06) 163
were associated with funding preferences. Compared with respondents rating themselves as in very 164 good health, respondents who rated themselves as in good, average, or poor/very poor health were 165 significantly more likely to assign a top ranking to medicines targeting diseases that affect patients 166 who are not financially well off (OR= 1.90, 95% CI= 1.13 to 3.20, p= 0.02; OR= 2.33, 95% CI= 1.35 to 167 4.01, p= 0.002; OR= 2.40, 95% CI= 1.20 to 4.79, p= 0.01 respectively), and to medicines that cost the 168 government more and thereby save patients more in out-of-pocket costs (OR= 2.25, 95% CI= 1.19 to 169 4.26, p= 0.01; OR= 2.18, 95% CI= 1.11 to 4.28, p= 0.02; OR= 3.12, 95% CI= 1.39 to 7.02, p= 0.006 170 respectively). Respondents who do not have private health insurance were significantly more likely 171 to allocate the highest funding priority to medicines that cost the government more, thereby saving 172 patients more in out-of-pocket costs compared to those with private health insurance (OR= 1.58, 173 95% CI= 1.07 to 2.31, p= 0.02). , 174
Discussion
175
The results of our study give a clear picture of public preferences regarding resource allocation for 176 medicines. The targeting of severe or life threatening diseases is clearly and by far the most 177 important prioritisation criterion , followed by medicines targeting diseases affecting children, 178 cancer medicines and medicines targeting diseases for which no treatment alternative is available. 179
Whilst the first three top ranking prioritisation criteria were assigned a least important ranking by a 180 small proportion of respondents (1 to 2.4%). Medicines targeting a disease for which no alternative 181 treatment exists were ranked most and least important by a similar proportion of respondents (8.6% 182 and 7.7%, respectively). One possible explanation for this variation is that societal opinion on the use 183 of this as a prioritisation criterion for new medicines funding may be divided and 'polarised'. 184
Further, findings from this study resonate with previous studies 11, 17, 19, 21, 22 , which have shown that 185 members of the general public give higher priority to medicines used for the treatment of severe 186 illness and for those with no available alternatives. The finding of support for prioritising anti-cancer 187 medicines is also generally consistent with existing evidence 23, 24 , and could explain the current focus 188 both in Australia and internationally on achieving timely access to such treatments 25 . However, as 189 cancer medicines are the only disease specific medicines explored in this study, this finding should 190 be interpreted with caution. We found no compelling evidence for prioritising end-of-life 191 treatments. This is consistent with a study by Linley et al 17 194 Our study suggests that rare disease therapies per se are not a strong driver for public funding 195 preferences. Although this is consistent with other research 17, 18 , it is nonetheless a somewhat 196 surprising finding given that rarity of disease is one of the four criteria that form the basis of the 'rule 197 of rescue' (RoR) PBAC claim 2 . A RoR applies in exceptional circumstances for drugs that provide a 198 worthwhile benefit for a severe and rare condition for which there is no alternative treatment 2, 9, 26 . 199 The results of our study suggest that the use of rarity of the disease as an inclusion criterion for LSDP 200 or as a basis for a RoR claim does not appear to be supported by the Australian public. One possible 201 interpretation of this result is that rarity is not a shared prioritisation criterion between the general 202 public and the PBAC. Given that rarity of the disease is linked to the total number of eligible patients 203 and cost for funding a medicine, it is, and may need to remain, an important prioritisation criterion 204 from the PBAC/government perspective, especially for high cost medicines. 205
An important strength of our study is that it included a large, broadly representative sample of 3080 206 adult Australians. However, due to the design of our study, non-completion rates and details of non-207 responders were unavailable for analysis or assessment for potential non-responder bias. Another 208 potential limitation relates to framing effects. It has been found that the choice of wording in 209 surveys is very important 27 . The results for the prioritisation criterion relating to life-style unrelated 210 diseases appear to be somewhat surprising, with the largest proportion of respondents ranking this 211 criterion last. It is possible that respondents' preferences may have been confounded by the 212 labelling choice used in the survey. Despite these limitations, our study has important implications 213 for health policy development with respect to the funding of new medicines in Australia. 214
Further, our research shows that respondents' funding preferences for access to new medicines are 215 influenced by their personal characteristics and circumstances. Therefore, if the general public's 216 views and preferences are to be included in the PBAC decision making process, a representative 217 sample is required. 218
In summary, the findings of this study provide assurance that the Australian public support some of 219 the currently used prioritisation criteria. However, quantification of criteria weights and equity 220 issues relative to other factors will require further research in order to provide guidance to the PBAC 221 on the cardinality of equity preferences and quantification of ICER increase to account for the 222 specific equity issues/criteria identified. 223
Conclusions 224
The reimbursement of prescribed medicines should reflect both evidence of safety and 225 effectiveness, and social values 28 . As such, it is important to understand societal views and 226 preferences for the distribution of healthcare spending. Results of this study provide useful 227 information on public preferences related to the equity aspects of government spending on 228 prescribed medicines in Australia. Understanding of public preferences on funding of new medicines 229 could help the PBAC/government determine circumstances in which greater emphasis on equity is 230 required, and how equity might be defined and achieved in a manner that is congruent with the 231 values of the Australian population. To ensure that public preferences are reflected in the PBAC's 232 assessments and recommendations, there is a need for further research to determine the best way 233 to incorporate these preferences into PBAC decision making processes. This will, in turn, improve 234 alignment between government and societal preferences for funding of new medicines 29, 30 . 235 
Cost to the PBS and savings to patient
Preference for funding should be given to new medicines that cost the government more and thereby save patients more in out-of-pocket costs 139 (4.5) 288 (9.4) 474 (5.1)
Medicines that help patients return to work
Preference for funding should be given to new medicines that help patients return to work 133 (4.3) 200 (6.5) 508 (5.5)
Carer burden
Preference for funding should be given to new medicines targeting diseases that, if untreated, cause patients to be reliant on carers 110 (3.6) 146 (4.7) 594 (6.4)
Life style related diseases and individual responsibility
Preference for funding should be given to new medicines targeting diseases that are not considered to be a life-style related disease i.e. diseases that could not be avoided through individual life style changes 109 (3.5) 1041 (33.8)
296
(3.2)
Significant innovation
Preference for funding should be given to new medicines that work in a new and different way to existing treatments 107 (3.5) 221 (7.2) 569 (6.2)
End-of-life treatments
Preference for funding should be given to new medicines that prolong life -even for a few months-at the end of life i.e. for patients with a life expectancy of less than 2 years 63 (2.0) 476 (15.5) 363 (3.9)
Rare diseases
Preference for funding should be given to new medicines targeting rare diseases i.e. diseases affecting less than 2000 patients in Australia 51 (1.7) 151 (4.9)
